Found: 33
Select item for more details and to access through your institution.
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 8, p. 1543, doi. 10.1007/s00432-017-2378-6
- By:
- Publication type:
- Article
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Applied Health Economics & Health Policy, 2019, v. 17, n. 4, p. 555, doi. 10.1007/s40258-019-00489-0
- By:
- Publication type:
- Article
Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia.
- Published in:
- Cell Death Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41420-022-01071-9
- By:
- Publication type:
- Article
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 5, p. 915, doi. 10.1111/bjh.17392
- By:
- Publication type:
- Article
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 5, p. 683, doi. 10.1111/bjh.13346
- By:
- Publication type:
- Article
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 4, p. 421, doi. 10.1002/ajh.26463
- By:
- Publication type:
- Article
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐dependence, minimizing undesirable drug–drug interactions
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 4, p. 644, doi. 10.1111/ejh.14059
- By:
- Publication type:
- Article
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 6, p. 617, doi. 10.1111/ejh.13699
- By:
- Publication type:
- Article
Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia.
- Published in:
- Oncology, 1990, v. 47, n. 2, p. 112, doi. 10.1159/000226800
- By:
- Publication type:
- Article
The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 4, p. 398, doi. 10.1111/ejh.12845
- By:
- Publication type:
- Article
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 1, p. 57, doi. 10.1111/ejh.12785
- By:
- Publication type:
- Article
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 4, p. 387, doi. 10.1111/ejh.12743
- By:
- Publication type:
- Article
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study ( Nord CML006).
- Published in:
- European Journal of Haematology, 2015, v. 94, n. 3, p. 243, doi. 10.1111/ejh.12423
- By:
- Publication type:
- Article
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
- Published in:
- European Journal of Haematology, 2002, v. 68, n. 3, p. 180, doi. 10.1034/j.1600-0609.2002.01530.x
- By:
- Publication type:
- Article
Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology.
- Published in:
- European Journal of Haematology, 1997, v. 58, n. 4, p. 241, doi. 10.1111/j.1600-0609.1997.tb01661.x
- By:
- Publication type:
- Article
Extramedullary progression of multiple myeloma following GM-CSF treatment - grounds for caution?
- Published in:
- European Journal of Haematology, 1992, v. 49, n. 2, p. 108, doi. 10.1111/j.1600-0609.1992.tb00040.x
- By:
- Publication type:
- Article
Chronic myeloid leukemia presenting late in pregnancy. Report of a case and a questionnaire reflecting diversity in management options.
- Published in:
- 2009
- By:
- Publication type:
- Letter
The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.
- Published in:
- Cell Death & Disease, 2021, v. 12, n. 10, p. 1, doi. 10.1038/s41419-021-04154-0
- By:
- Publication type:
- Article
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
- Published in:
- PLoS ONE, 2017, v. 12, n. 1, p. 1, doi. 10.1371/journal.pone.0171041
- By:
- Publication type:
- Article
Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasia.
- Published in:
- Hematological Oncology, 1991, v. 9, n. 3, p. 129, doi. 10.1002/hon.2900090303
- By:
- Publication type:
- Article
Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 8, p. 760, doi. 10.1002/ajh.23238
- By:
- Publication type:
- Article
Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 16, p. 3076, doi. 10.1002/cncr.28098
- By:
- Publication type:
- Article
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C<sub>4</sub> synthase expression and activity in chronic myeloid leukaemia.
- Published in:
- 2008
- By:
- Publication type:
- Letter
research paper Abnormal LTC<sub>4</sub> synthase RNA degradation in neutrophils from CML patients.
- Published in:
- British Journal of Haematology, 2004, v. 124, n. 6, p. 739, doi. 10.1111/j.1365-2141.2004.04848.x
- By:
- Publication type:
- Article
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 4, p. 1048, doi. 10.1046/j.1365-2141.2002.03765.x
- By:
- Publication type:
- Article
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 3, p. 748, doi. 10.1046/j.1365-2141.2002.03685.x
- By:
- Publication type:
- Article
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Intensive Treatment and Stem Cell Transplantation in Chronic Myelogenous Leukemia: Long-Term Follow-Up.
- Published in:
- Acta Haematologica, 2005, v. 113, n. 3, p. 155, doi. 10.1159/000084445
- By:
- Publication type:
- Article
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
- Published in:
- Oncology Reports, 2018, v. 40, n. 2, p. 902, doi. 10.3892/or.2018.6465
- By:
- Publication type:
- Article
Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4 synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate.
- Published in:
- British Journal of Haematology, 1998, v. 101, n. 4, p. 728, doi. 10.1046/j.1365-2141.1998.00752.x
- By:
- Publication type:
- Article
Elevated white blood cell synthesis of leukotriene C<sub>4</sub> in chronic myelogenous leukaemia but not in polycythaemia vera.
- Published in:
- British Journal of Haematology, 1990, v. 74, n. 3, p. 257, doi. 10.1111/j.1365-2141.1990.tb02580.x
- By:
- Publication type:
- Article